We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-25.00 | -0.56% | 4,450.00 | 4,400.00 | 4,500.00 | 4,475.00 | 4,450.00 | 4,475.00 | 1,007 | 09:25:35 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 27.69 | 231.82M |
TIDMBVXP Bioventix plc ("Bioventix" or "the Company") Issue of Equity Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has applied for 1,000 ordinary shares of 5 pence each (the "Option Shares") to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and that dealings will commence in the Option Shares on 4 February 2019. The Option Shares are being issued pursuant to the exercise of options by an employee of the Company. The Option Shares will rank pari passu with the existing ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares"). The total number of Ordinary Shares in issue following Admission will be 5,141,674 and the Company holds no shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 5,141,674. The above figure of 5,141,674 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA's Disclosure Guidance and Transparency Rules. For further information please contact: Bioventix plc Chief Executive Officer Tel: 01252 728 001 Peter Harrison finnCap Ltd Corporate Finance Tel: 020 7220 0500 Geoff Nash/Simon Hicks ECM Alice Lane About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP. END
(END) Dow Jones Newswires
January 29, 2019 02:00 ET (07:00 GMT)
1 Year Bioventix Chart |
1 Month Bioventix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions